Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Assets Average (2016 - 2025)

Historic Assets Average for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to $380.8 million.

  • Cartesian Therapeutics' Assets Average fell 516.6% to $380.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.8 million, marking a year-over-year decrease of 516.6%. This contributed to the annual value of $370.0 million for FY2024, which is 5714.94% up from last year.
  • Cartesian Therapeutics' Assets Average amounted to $380.8 million in Q3 2025, which was down 516.6% from $399.0 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Assets Average peaked at $445.2 million during Q4 2024, and registered a low of $122.8 million during Q3 2023.
  • Moreover, its 5-year median value for Assets Average was $178.6 million (2021), whereas its average is $247.3 million.
  • In the last 5 years, Cartesian Therapeutics' Assets Average tumbled by 3297.36% in 2023 and then surged by 22705.63% in 2024.
  • Cartesian Therapeutics' Assets Average (Quarter) stood at $163.5 million in 2021, then grew by 5.23% to $172.1 million in 2022, then grew by 19.45% to $205.5 million in 2023, then soared by 116.58% to $445.2 million in 2024, then dropped by 14.46% to $380.8 million in 2025.
  • Its last three reported values are $380.8 million in Q3 2025, $399.0 million for Q2 2025, and $422.1 million during Q1 2025.